EVEROLIMUS ETHYPHARM 5 mg TABLETS

Introduction

Package Leaflet: Information for the Patient

Everolimus Ethypharm 5 mgEFG tablets

Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.

• Keep this package leaflet, as you may need to read it again.
• If you have any questions, consult your doctor or pharmacist.
• This medication has been prescribed to you only, and you should not give it to others, even if they have the same symptoms as you, as it may harm them.
• If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. See section 4.

Contents of the Package Leaflet

1. What is Everolimus Ethypharm and what is it used for
2. What you need to know before taking Everolimus Ethypharm
3. How to take Everolimus Ethypharm
4. Possible side effects
5. Storage of Everolimus Ethypharm
6. Package contents and additional information

1. What is Everolimus Ethypharm and what is it used for

Everolimus Ethypharm is a cancer medication that contains the active substance everolimus. Everolimus reduces blood supply to the tumor and delays the growth and spread of cancer cells.

Everolimus Ethypharm is used to treat adult patients with:

• advanced breast cancer with positive hormonal receptor in postmenopausal women, in whom other treatments (called "non-steroidal aromatase inhibitors") can no longer keep the disease under control. It is administered along with a type of medication called exemestane, a steroidal aromatase inhibitor, used for hormonal treatment of cancer.
• advanced tumors called neuroendocrine tumors that originate in the stomach, intestine, lung, or pancreas. It is administered if the tumors are not operable and do not produce excess specific hormones or other related natural substances.
• advanced kidney cancer (advanced renal cell carcinoma), when other treatments (called anti-VEGF treatment) have not helped to stop the disease.

2. What you need to know before taking Everolimus Ethypharm

Everolimus Ethypharm will only be prescribed to you by a doctor with experience in cancer treatment. Follow your doctor's instructions carefully. They may be different from the general information contained in this package leaflet. If you have questions about Everolimus Ethypharm or why you have been prescribed this medication, consult your doctor.

Do not take Everolimus Ethypharm

• if you are allergicto everolimus, to related substances such as sirolimus or temsirolimus, or to any of the other components of this medication (listed in section 6).

If you think you may be allergic, consult your doctor.

Warnings and precautions

Consult your doctor before starting to take Everolimus Ethypharm:

• if you have liver problems or if you have had a disease that may have affected your liver. In this case, your doctor may prescribe a different dose of everolimus.
• if you have diabetes (high blood sugar). Everolimus may increase blood sugar levels and worsen diabetes mellitus. This may require treatment with insulin and/or oral antidiabetic medications. Inform your doctor if you notice excessive thirst or need to urinate more frequently.
• if you need to receive a vaccine while taking everolimus.
• if you have high cholesterol. Everolimus may increase cholesterol and/or other blood fats.
• if you have recently undergone major surgery, or if you still have an unhealed wound after surgery. Everolimus may increase the risk of wound healing problems.
• if you have an infection. It may be necessary to treat your infection before starting treatment with everolimus.
• if you have previously had hepatitis B, as it may reactivate during treatment with everolimus (see section 4 "Possible side effects").
• if you have received or are about to receive radiation therapy.

Everolimus may also:

• weaken your immune system. Therefore, you may be at risk of infection while taking everolimus. If you have a fever or other signs of infection, consult your doctor. Some infections can be serious and life-threatening.
• affect kidney function. Therefore, your doctor will monitor your kidney function while you are taking everolimus.
• cause difficulty breathing, coughing, and fever.
• cause the appearance of ulcers and sores in the mouth. Your doctor may need to interrupt or stop treatment with Afinitor. You may need treatment with a mouthwash, gel, or other products. Some mouthwashes and gels can worsen ulcers, so do not try any without consulting your doctor first. Your doctor may restart treatment with Afinitor at the same dose or a lower dose.

Tell your doctorif you experience these symptoms.

During treatment, you will undergo periodic blood tests. These tests will determine the number of cells in the blood (white blood cells, red blood cells, and platelets) to check if everolimus is having an unwanted effect on these cells. You will also undergo blood tests to monitor kidney function (creatinine level), liver function (transaminase level), and blood sugar and cholesterol levels. These tests are performed because they may be affected by treatment with everolimus.

Children and adolescents

Everolimus Ethypharm should not be administered to children or adolescents (under 18 years of age).

Other medications and Everolimus Ethypharm

Everolimus Ethypharm may affect how other medications work. If you are taking other medications at the same time as Everolimus Ethypharm, your doctor may change the dose of Everolimus Ethypharm or the other medications.

Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medication.

The following may increase the risk of side effects with everolimus:

• ketoconazole, itraconazole, voriconazole, or fluconazole, and other antifungal medications used to treat fungal infections.
• clarithromycin, telithromycin, or erythromycin, antibiotics used to treat bacterial infections.
• ritonavir and other medications used to treat HIV/AIDS.
• verapamil or diltiazem, used to treat heart problems or high blood pressure.
• dronedarone, a medication used to help regulate your heart rhythm.
• cyclosporine, a medication used to prevent the body from rejecting transplanted organs.
• imatinib, used to inhibit the growth of abnormal cells.
• angiotensin-converting enzyme (ACE) inhibitors (such as ramipril) used to treat high blood pressure or other cardiovascular problems.
• nefazodone, used to treat depression.
• cannabidiol (its use includes, among others, the treatment of epileptic seizures).

The following may reduce the effectiveness of Everolimus Ethypharm:

• rifampicin, used to treat tuberculosis (TB).
• efavirenz or nevirapine, used to treat HIV/AIDS.
• St. John's Wort (Hypericum perforatum), a herbal product used to treat depression and other conditions.
• dexamethasone, a corticosteroid used to treat a wide range of conditions, including inflammatory or immune system problems.
• phenytoin, carbamazepine, or phenobarbital, and other antiepileptics used to control seizures or attacks.

These medications should be avoided during treatment with everolimus. If you are taking any of them, your doctor may prescribe a different medication or change your dose of everolimus.

Taking Everolimus Ethypharm with food and drinks

Do not take grapefruit or grapefruit juice while taking Everolimus Ethypharm. It may increase the amount of Everolimus Ethypharm in the blood, possibly to a harmful level.

Pregnancy, breastfeeding, and fertility

Pregnancy

Everolimus may harm the fetus, and treatment with everolimus is not recommended during pregnancy. Tell your doctor if you are pregnant or think you may be pregnant. Your doctor will discuss with you whether you should take this medication during pregnancy.

Women who can become pregnant must use a highly effective contraceptive method during treatment and up to 8 weeks after finishing treatment. If, despite these measures, you think you may be pregnant, consult your doctor beforetaking this medication again.

Breastfeeding

Everolimus may harm the breastfed baby. Do not breastfeed during treatment and for 2 weeks after the last dose of everolimus. Tell your doctor if you are breastfeeding.

Female fertility

In some patients treated with everolimus, absence of menstrual periods (amenorrhea) has been observed.

Everolimus may affect female fertility. Tell your doctor if you want to have children.

Male fertility

Everolimus may affect male fertility. Consult your doctor if you want to be a father.

Driving and using machines

If you feel abnormally tired (fatigue is a very common side effect), be especially careful when driving or using machines.

Everolimus Ethypharm contains lactose

This medication contains lactose (milk sugar). If your doctor has told you that you have an intolerance to certain sugars, consult your doctor before taking this medication.

3. How to take Everolimus Ethypharm

Follow your doctor's or pharmacist's instructions for taking this medication exactly. If you are unsure, consult your doctor or pharmacist again.

The recommended dose is 10 mg, once a day. Your doctor will tell you how many Everolimus Ethypharm tablets to take.

If you have liver problems, your doctor may start treatment with a lower dose of Everolimus Ethypharm (2.5; 5; or 7.5 mg per day).

If you experience side effects while taking Everolimus Ethypharm (see section 4), your doctor may reduce the dose you take or interrupt treatment for a short period or permanently.

Take Everolimus Ethypharm once a day, more or less at the same time, always with food or always without food.

Swallow the tablet(s) whole with a glass of water. The tablets should not be chewed or crushed.

If you take more Everolimus Ethypharm than you should

• If you have taken too much Everolimus Ethypharm, or if someone has taken your tablets accidentally, consult your doctor or go to the hospital immediately. Urgent treatment may be necessary.
• Take the package and this package leaflet with you so that the doctor knows what you have taken.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service (Tel. 91 562 04 20) indicating the medication and the amount ingested.

If you forget to take Everolimus Ethypharm

If you have missed a dose, take the next dose at the scheduled time. Do not take a double dose to make up for missed doses.

If you stop taking Everolimus Ethypharm

Do not stop taking Everolimus Ethypharm unless your doctor tells you to.

If you have any further questions about the use of this medication, ask your doctor or pharmacist.

4. Possible Adverse Effects

Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.

STOP treatment with everolimus and seek immediate medical attention if you experience any of the following signs of an allergic reaction:

• Difficulty breathing or swallowing
• Swelling of the face, lips, tongue, or throat

• Severe skin itching, with red-colored rash or bumps on the skin

Severe adverse effects of everolimus include:

Very Common(may affect more than 1 in 10 people)

• Increased temperature, chills (signs of infection)
• Fever, cough, difficulty breathing, wheezing (signs of lung inflammation, also known as pneumonitis)

Common(may affect up to 1 in 10 people)

• Excessive thirst, high urine output, increased appetite with weight loss, fatigue (signs of diabetes)
• Bleeding (hemorrhage), for example in the intestinal wall
• Significant decrease in urine output (sign of renal failure)

Uncommon(may affect up to 1 in 100 people)

• Fever, skin rash, joint pain and inflammation, as well as fatigue, loss of appetite, nausea, yellowing of the skin (jaundice), pain in the upper right abdomen, pale stools, dark urine (may be signs of hepatitis B reactivation)
• Shortness of breath, difficulty breathing when lying down, swelling of the feet or legs (signs of heart failure)
• Swelling and/or pain in one leg, usually in the calf, redness or warmth of the skin in the affected area (signs of blockage of a blood vessel (vein) in the legs caused by a blood clot)
• Sudden onset of breathing problems, chest pain or coughing up blood (potential signs of pulmonary embolism, a situation that occurs when one or more arteries in the lungs are blocked)

potential signs of pulmonary embolism, a situation that occurs when one or more arteries in the lungs are blocked)

• Significant decrease in urine output, swelling in the legs, feeling of confusion, back pain (signs of sudden renal failure)
• Rash, itching, acne, difficulty breathing or swallowing, dizziness (signs of a severe allergic reaction, also known as hypersensitivity)

Rare(may affect up to 1 in 1,000 people)

• Difficulty breathing or rapid breathing (signs of respiratory distress syndrome)

If you experience any of these adverse effects, inform your doctor immediately as they could have fatal consequences.

Other possible adverse effects of everolimus include:

Very Common(may affect more than 1 in 10 people)

• High blood sugar levels (hyperglycemia)
• Loss of appetite
• Taste disturbance (dysgeusia)
• Headache
• Nosebleeds (epistaxis)
• Cough
• Mouth ulcers
• Stomach discomfort including feeling of nausea or diarrhea
• Skin rash
• Itching (pruritus)
• Feeling of weakness or fatigue
• Fatigue, difficulty breathing, dizziness, pale skin, signs of low red blood cell count (anemia)

low red blood cell count (anemia)

• Swelling of the arms, hands, feet, ankles, or other parts of the body (signs of edema)
• Weight loss
• High lipid levels in the blood (hypercholesterolemia)

Common(may affect up to 1 in 10 people)

• Spontaneous bleeding or bruising (signs of low platelet count, also known as thrombocytopenia)
• Difficulty breathing (dyspnea)
• Thirst, low urine output, dark urine, dry reddened skin, irritability (signs of dehydration)
• Sleeping problems (insomnia)
• Headache, dizziness (sign of high blood pressure, also known as hypertension)
• Swelling of a part or all of the arm (including fingers) or leg (including toes), feeling of heaviness, limited mobility, discomfort (possible symptoms of lymphedema
• Fever, sore throat, mouth ulcers due to infections (signs of low white blood cell count, leucopenia, lymphopenia, and/or neutropenia)
• Fever
• Inflammation of the mucous membrane inside the mouth, stomach, intestine
• Dry mouth
• Heartburn (dyspepsia)
• Vomiting
• Difficulty swallowing (dysphagia)
• Abdominal pain
• Acne
• Rash and pain on the palms of the hands or soles of the feet (palmar-plantar syndrome)
• Redness of the skin (erythema)
• Joint pain
• Mouth pain
• Menstrual disorders such as irregular periods
• High lipid levels in the blood (hyperlipidemia, increased triglycerides)
• Low potassium levels in the blood (hypokalemia)
• Low phosphate levels in the blood (hypophosphatemia)
• Low calcium levels in the blood (hypocalcemia)
• Dry skin, skin peeling, skin lesions
• Nail disorders, nail breakage
• Mild hair loss
• Abnormal liver function tests (increased alanine and aspartate aminotransferase)
• Abnormal kidney function tests (increased creatinine)
• Eyelid swelling
• Protein in the urine

Uncommon(may affect up to 1 in 100 people)

• Weakness, spontaneous bleeding or bruising, and frequent infections with signs such as fever, chills, sore throat, or mouth ulcers (signs of low blood cell count, also known as pancytopenia)
• Loss of taste (ageusia)
• Coughing up blood (hemoptysis)
• Menstrual disorders such as absence of periods (amenorrhea)
• Frequent urination during the day
• Chest pain
• Abnormal wound healing
• Hot flashes
• Tearing with itching and redness, or pink or red eye (conjunctivitis)

Rare(may affect up to 1 in 1,000 people)

• Fatigue, difficulty breathing, dizziness, pale skin (signs of low red blood cell count, possibly due to a type of anemia called pure red cell aplasia)
• Swelling of the face, around the eyes, mouth, and inner mouth and/or throat, as well as the tongue and difficulty breathing or swallowing (also known as angioedema), may be signs of an allergic reaction

Frequency Not Known(cannot be estimated from the available data)

• Reaction at the site of previous radiation therapy (e.g., skin redness or lung inflammation) (called radiation recall syndrome)
• Worsening of radiation therapy side effects

If these adverse reactions worsen, inform your doctor and/or pharmacist. Most adverse effects are mild to moderate and usually disappear if treatment is interrupted for a few days.

Reporting Adverse Effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Medicines Surveillance System for Human Use: www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.

5. Storage of Everolimus Ethypharm

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiration date stated on the packaging and blister. The expiration date is the last day of the month indicated.

This medicine does not require any special storage temperature

Store in the original packaging to protect it from light.

Open the blister just before taking the tablets.

Do not use this medicine if you notice that the packaging is damaged or shows signs of tampering.

Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.

6. Package Contents and Additional Information

Composition of Everolimus Ethypharm

• The active ingredient is everolimus.

Each Everolimus Ethypharm tablet contains 2.5 mg of everolimus.

• The other ingredients are butylhydroxytoluene (E321), hypromellose, lactose monohydrate, crospovidone, lactose, and magnesium stearate.

Appearance and Package Contents

Everolimus Ethypharm 2.5 mg tablets are oblong, white to off-white, 9.6 x 4.5 mm. They are marked with "E" on one side and "2.5" on the other.

Everolimus Ethypharm 2.5 mg is available in packs containing 30 or 90 tablets.

Not all pack sizes may be marketed.

Marketing Authorization Holder

Ethypharm

194 Bureaux de la Colline – Bâtiment D

92213 Saint-Cloud cedex

France

Manufacturer

Ethypharm

Chemin de la Poudrière

76120 Grand Quevilly

France

Ethypharm

Z.I. de Saint Arnoult

28170 Châteauneuf en Thymerais

France

You can request more information about this medicine by contacting the local representative of the marketing authorization holder:

ALTAN PHARMACEUTICALS S.A.

C/Colquide, Nº 6, Portal 2, 1ª planta, Oficina F. Edificio Prisma

Las Rozas (Madrid)

28230 Spain

This medicine is authorized in the Member States of the European Economic Area under the following names:

Date of the last revision of this leaflet 04/2023.

Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.